Arlene A Forastiere

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group
    Michael K Gibson
    Department of Medical Oncology, Sidney Kimmell Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    J Clin Oncol 23:3562-7. 2005
  2. pmc Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer
    Arlene A Forastiere
    Sydney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Clin Oncol 31:845-52. 2013
  3. pmc Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group
    Harry H Yoon
    Mayo Clinic, Rochester, MN 55905, USA
    BMC Cancer 11:176. 2011
  4. doi request reprint Chemotherapy in the treatment of locally advanced head and neck cancer
    Arlene A Forastiere
    Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, Maryland 21231, USA
    J Surg Oncol 97:701-7. 2008
  5. ncbi request reprint Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer
    Arlene A Forastiere
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    N Engl J Med 349:2091-8. 2003
  6. pmc Impact of surgeon and hospital volume on short-term outcomes and cost of oropharyngeal cancer surgical care
    Christine G Gourin
    Department of Otolaryngology Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Laryngoscope 121:746-52. 2011
  7. doi request reprint Impact of surgeon and hospital volume on short-term outcomes and cost of laryngeal cancer surgical care
    Christine G Gourin
    Department of Otolaryngology Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Laryngoscope 121:85-90. 2011
  8. ncbi request reprint Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer
    Lawrence Kleinberg
    Sidney Kimmel Oncology Center at Johns Hopkins, Baltimore, MD 21231, USA
    Int J Radiat Oncol Biol Phys 56:328-34. 2003
  9. doi request reprint Volume-based trends in surgical care of patients with oropharyngeal cancer
    Christine G Gourin
    Department of Otolaryngology Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Laryngoscope 121:738-45. 2011
  10. ncbi request reprint Combined-modality therapy for esophageal cancer: are we making progress?
    Michael K Gibson
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Cancer J 9:238-40. 2003

Research Grants

  1. EASTERN COOPERATIVE ONCOLOGY GROUP
    Arlene Forastiere; Fiscal Year: 2007

Detail Information

Publications47

  1. ncbi request reprint Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group
    Michael K Gibson
    Department of Medical Oncology, Sidney Kimmell Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    J Clin Oncol 23:3562-7. 2005
    ....
  2. pmc Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer
    Arlene A Forastiere
    Sydney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Clin Oncol 31:845-52. 2013
    ..To report the long-term results of the Intergroup Radiation Therapy Oncology Group 91-11 study evaluating the contribution of chemotherapy added to radiation therapy (RT) for larynx preservation...
  3. pmc Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group
    Harry H Yoon
    Mayo Clinic, Rochester, MN 55905, USA
    BMC Cancer 11:176. 2011
    ..As a secondary aim, we investigated the rate of allelic imbalance between germline and tumor DNA...
  4. doi request reprint Chemotherapy in the treatment of locally advanced head and neck cancer
    Arlene A Forastiere
    Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, Maryland 21231, USA
    J Surg Oncol 97:701-7. 2008
    ..The focus of future trials should be on survival improvement, toxicity reduction and risk stratification for treatment decision making...
  5. ncbi request reprint Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer
    Arlene A Forastiere
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    N Engl J Med 349:2091-8. 2003
    ..The value of adding chemotherapy to radiotherapy and the optimal timing of chemotherapy are unknown...
  6. pmc Impact of surgeon and hospital volume on short-term outcomes and cost of oropharyngeal cancer surgical care
    Christine G Gourin
    Department of Otolaryngology Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Laryngoscope 121:746-52. 2011
    ..To evaluate the impact of surgeon and hospital case volume and other related variables on short-term outcomes after surgery for oropharyngeal cancer...
  7. doi request reprint Impact of surgeon and hospital volume on short-term outcomes and cost of laryngeal cancer surgical care
    Christine G Gourin
    Department of Otolaryngology Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Laryngoscope 121:85-90. 2011
    ..To evaluate the impact of surgeon and hospital case volume and other related variables on short-term outcomes after surgery for laryngeal cancer...
  8. ncbi request reprint Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer
    Lawrence Kleinberg
    Sidney Kimmel Oncology Center at Johns Hopkins, Baltimore, MD 21231, USA
    Int J Radiat Oncol Biol Phys 56:328-34. 2003
    ..To assess the long-term survival results after cisplatin, protracted infusion 5-fluorouracil, and concurrent radiotherapy (RT) followed by surgical resection of esophageal cancer...
  9. doi request reprint Volume-based trends in surgical care of patients with oropharyngeal cancer
    Christine G Gourin
    Department of Otolaryngology Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Laryngoscope 121:738-45. 2011
    ..Positive volume-outcome relationships exist for diseases treated with technically complex surgery. Contemporary patterns of oropharyngeal cancer surgery by hospital and surgeon volume are poorly defined...
  10. ncbi request reprint Combined-modality therapy for esophageal cancer: are we making progress?
    Michael K Gibson
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Cancer J 9:238-40. 2003
  11. pmc Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response?
    Robert A Meguid
    Division of Thoracic Surgery, Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA
    J Thorac Cardiovasc Surg 138:1309-17. 2009
    ..We hypothesized that most relapses in patients with esophageal cancer having neoadjuvant chemoradiation therapy would occur outside of the surgical and radiation fields...
  12. doi request reprint HPV-associated head and neck cancer: a virus-related cancer epidemic
    Shanthi Marur
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Lancet Oncol 11:781-9. 2010
    ....
  13. ncbi request reprint Chemoradiotherapy for localized esophageal cancer: regimen selection and molecular mechanisms of radiosensitization
    Lawrence Kleinberg
    Johns Hopkins University, MD, USA
    Nat Clin Pract Oncol 4:282-94. 2007
    ..The recent clinical development of biologic, targeted therapies provides a new avenue for the study of chemoradiotherapy and an opportunity to increase long-term survival...
  14. ncbi request reprint Neck dissection followed by radiotherapy or chemoradiotherapy for small primary oropharynx carcinoma with cervical metastasis
    Ashok N Reddy
    Department of Otolaryngology Head and Neck Surgery, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Laryngoscope 115:1196-200. 2005
    ..Our rationale for this algorithm and our results are examined...
  15. doi request reprint Challenges of integrating chemotherapy and targeted therapy with radiation in locally advanced head and neck squamous cell cancer
    Shanthi Marur
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Curr Opin Oncol 22:206-11. 2010
    ..This review will discuss some of the novel approaches to treating head and neck squamous cell cancer, particularly the introduction of biological agents into treatment paradigms, and some of the challenges arising as the field advances...
  16. ncbi request reprint Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: phase II trial (E8296) of the Eastern Cooperative Oncology Group
    Mary Armanios
    Johns Hopkins University, Baltimore, MD 21205, USA
    J Clin Oncol 22:4495-9. 2004
    ..To evaluate the effect of postoperative paclitaxel and cisplatin on 2-year survival in patients with completely resected adenocarcinoma of the distal esophagus, gastro-esophageal (GE) junction, and cardia...
  17. ncbi request reprint Multidisciplinary approaches in the management of advanced head and neck tumors: state of the art
    Michael K Gibson
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, Maryland 21231, USA
    Curr Opin Oncol 16:220-4. 2004
    ..This review presents selected advances in primary research in head and neck cancer during the year 2003...
  18. ncbi request reprint Chemoradiation in the management of esophageal cancer
    Lawrence Kleinberg
    Department of Radiation Oncology and Molecular Sciences, Division of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231 2410, USA
    J Clin Oncol 25:4110-7. 2007
    ....
  19. doi request reprint Head and neck cancer: changing epidemiology, diagnosis, and treatment
    Shanthi Marur
    Bunting Blaustein CRB1 G92, 1650 Orleans St, Baltimore, MD 21231 1000, USA smarur1 jhmi edu
    Mayo Clin Proc 83:489-501. 2008
    ....
  20. ncbi request reprint Reassessment of the role of induction chemotherapy for head and neck cancer
    Michael K Gibson
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231 1000, USA
    Lancet Oncol 7:565-74. 2006
    ..In this review we summarise data for the use of induction chemotherapy to define better which patients will likely benefit from this approach now and which questions are important in the design of future clinical trials...
  21. ncbi request reprint Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus
    Elisabeth I Heath
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Invest New Drugs 20:95-9. 2002
    ..The objective of this trial was to determine the complete and partial response rate of docetaxel in patients with incurable adenocarcinoma of the esophagus...
  22. ncbi request reprint Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma
    Malcolm V Brock
    Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Clin Cancer Res 9:2912-9. 2003
    ..The association of clinicopathological and biomolecular risk factors to survival and recurrence was performed using the Log-rank test and Cox proportional hazards model for multivariate analysis...
  23. doi request reprint Volume-based trends in laryngeal cancer surgery
    Christine G Gourin
    Department of Otolaryngology Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Laryngoscope 121:77-84. 2011
    ..Positive volume-outcome relationships exist for diseases treated with technically complex surgery. Contemporary patterns of laryngeal cancer surgery by hospital and surgeon volume are poorly defined...
  24. doi request reprint Locally advanced esophageal adenocarcinoma: current standards and molecular predictors of outcome
    Harry H Yoon
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1550 Orleans Street, CRB2 5M 41, Baltimore, MD 21231, USA
    Future Oncol 4:413-25. 2008
    ..We attempt to clarify the somewhat unwieldy body of literature in this area, with a focus on adenocarcinoma, keeping the clinician and clinical researcher particularly in mind...
  25. ncbi request reprint Head and neck cancer: recent advances and new standards of care
    Arlene A Forastiere
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Clin Oncol 24:2603-5. 2006
  26. ncbi request reprint Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications
    Eric L Powell
    Department of Pathology, Johns Hopkins University, Baltimore, MD, USA
    Am J Surg Pathol 29:1497-504. 2005
    ..This loss of MTAP during 9p21 homozygous deletion might be exploited therapeutically using de novo purine synthesis antimetabolites to treat a subset of invasive gastroesophageal adenocarcinomas and esophageal precursor lesions...
  27. doi request reprint Volume-based trends in thyroid surgery
    Christine G Gourin
    Department of Otolaryngology Head and Neck Surgery, The Johns Hopkins University, 601 N Caroline St, Ste 6260, Baltimore, MD 21287, USA
    Arch Otolaryngol Head Neck Surg 136:1191-8. 2010
    ..to characterize contemporary patterns of thyroid surgical care and variables associated with access to high-volume care...
  28. ncbi request reprint Postesophagectomy morbidity, mortality, and length of hospital stay after preoperative chemoradiation therapy
    John R Doty
    Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Ann Thorac Surg 74:227-31; discussion 231. 2002
    ..Whether preoperative therapy increases postesophagectomy morbidity and mortality has not been determined. This study evaluates our postoperative results after chemoradiation therapy...
  29. pmc Clinical correlates of promoter hypermethylation of four target genes in head and neck cancer: a cooperative group correlative study
    Jong Lyel Roh
    Authors Affiliations Departments of Otolaryngology Head and Neck Surgery and Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea and Dana Farber Cancer Institute and Harvard School of Public Health, Boston, Massachusetts
    Clin Cancer Res 19:2528-40. 2013
    ....
  30. ncbi request reprint Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions
    Arlene A Forastiere
    J Clin Oncol 25:2152-5. 2007
  31. ncbi request reprint Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer
    Dong M Shin
    Department of Thoracic Head and Neck Medical Oncology, Diagnostic Imaging, Biostatistics, Head and Neck Surgery, and Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4095, USA
    J Clin Oncol 20:364-70. 2002
    ..The purpose of this study was to test interferon alfa (IFNalpha), 13-cis-retinoic acid (13cRA), and cisplatin biochemotherapy in advanced squamous cell carcinoma (SCC) of the skin...
  32. ncbi request reprint Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck
    Bonnie S Glisson
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:1593-9. 2002
    ..To assess the antitumor activity and toxicity of docetaxel plus cisplatin chemotherapy in patients with recurrent or incurable squamous cell carcinoma of the head and neck (SCCHN)...
  33. ncbi request reprint Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group
    Corey J Langer
    Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Invest 22:823-31. 2004
    ..Protracted exposure to paclitaxel may overcome resistance observed by using shorter infusions. Therefore we sought to evaluate paclitaxel by 96-hour infusion in both treatment-naïve and previously treated patients with SCCHN...
  34. ncbi request reprint Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck
    Jay S Cooper
    New York University Medical Center, New York, USA
    N Engl J Med 350:1937-44. 2004
    ..We tested the hypothesis that concurrent postoperative administration of cisplatin and radiotherapy would improve the rate of local and regional control...
  35. ncbi request reprint Organ preservation trials for laryngeal cancer
    Jill Gilbert
    Louisiana State University, Health Sciences Center Stanley, C Scott Cancer Center, 433 Bolivar Street, New Orleans, LA 70112, USA
    Otolaryngol Clin North Am 35:1035-54, vi. 2002
    ....
  36. ncbi request reprint Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study
    Barbara Burtness
    Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA
    J Clin Oncol 23:8646-54. 2005
    ..These cancers are rich in epidermal growth factor receptor (EGFR). We wished to determine whether the addition of cetuximab, which inhibits activation of EGFR, would improve PFS...
  37. ncbi request reprint An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer
    David J Adelstein
    Cleveland Clinic Foundation, Department of Hematology and Medical Oncology, Ohio 44195, USA
    J Clin Oncol 21:92-8. 2003
    ..The Head and Neck Intergroup conducted a phase III randomized trial to test the benefit of adding chemotherapy to radiation in patients with unresectable squamous cell head and neck cancer...
  38. ncbi request reprint Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group
    Jill Gilbert
    Louisiana State University Medical Center, New Orleans, Louisiana, USA
    Head Neck 28:197-204. 2006
    ..The Eastern Cooperative Oncology Group (ECOG) initiated a phase II evaluation of paclitaxel in patients with locally recurrent or metastatic salivary gland malignancies...
  39. ncbi request reprint Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy
    Athanassios Argiris
    Feinberg School of Medicine, Division of Hematology Oncology, Northwestern University, Chicago, IL 60611, USA
    J Clin Oncol 22:262-8. 2004
    ..To evaluate the outcome of elderly patients with head and neck cancer undergoing palliative chemotherapy...
  40. ncbi request reprint Organ preservation for cancer of the larynx: current indications and future directions
    Jill Gilbert
    Louisiana State University Health Sciences Center, Stanley S Scott Cancer Center, New Orleans, LA, USA
    Semin Radiat Oncol 14:167-77. 2004
    ..It remains to be seen whether such interventions can improve on the excellent locoregional control shown in the landmark Intergroup trial...
  41. ncbi request reprint American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer
    David G Pfister
    American Society of Clinical Oncology, Alexandria, VA, VA 22314, USA
    J Clin Oncol 24:3693-704. 2006
    ..This guideline is intended for use by oncologists in the care of patients outside of clinical trials...
  42. ncbi request reprint Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma
    Elisabeth I Heath
    Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA
    Invest New Drugs 24:135-40. 2006
    ..The objectives of the trial were to determine pathologic complete response rate (pCR), overall response rate, progression-free survival, pattern of disease relapse, and two-year and overall survival...
  43. ncbi request reprint Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399
    Anthony J Cmelak
    Vanderbilt University Medical Center, Nashville, TN 37232 5671, USA
    J Clin Oncol 25:3971-7. 2007
    ..This phase II multi-institutional trial evaluates taxane-based induction chemotherapy followed by CCR for organ preservation in resectable stage III/IVA and IVB larynx and oropharynx (OP) cancer patients...
  44. ncbi request reprint Is there a new role for induction chemotherapy in the treatment of head and neck cancer?
    Arlene A Forastiere
    J Natl Cancer Inst 96:1647-9. 2004
  45. doi request reprint Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago Division of Biological Sciences, 5801 S Ellis, Chicago, IL 60637, USA
    J Clin Oncol 26:4708-13. 2008
    ..This multi-institutional study assessed the activity and safety of axitinib, an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 in patients with advanced thyroid cancer...
  46. ncbi request reprint Head and neck cancers
    Arlene A Forastiere
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, USA
    J Natl Compr Canc Netw 3:316-91. 2005
  47. pmc Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial
    Elisabeth I Heath
    Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA
    J Natl Cancer Inst 99:545-57. 2007
    ....

Research Grants3

  1. EASTERN COOPERATIVE ONCOLOGY GROUP
    Arlene Forastiere; Fiscal Year: 2007
    ..Our accrual and committee involvement is expected to continue to grow because of expanding clinical programs and faculty made possible with a new Cancer Center facility and research buildings occupied since late 2000. ..